Advances in the Treatment of Multiple Sclerosis

Carolyn Goldschmidt, DO, Marisa P. McGinley, DO, MSc*

INTRODUCTION

Multiple sclerosis (MS) is an immune-mediated, inflammatory demyelinating disease of the central nervous system (CNS) that leads to irreversible disability and currently is estimated to affect nearly 1 million people in the United States and more than 2 million people globally.1,2 The most common disease type is relapsing remitting (85%–90%), and most treatments target this disease subtype. Some of these relapsing remitting MS (RRMS) patients will transition to a secondary progressive course. A small proportion of patients (10%) has primary progressive MS (PPMS), which is characterized by progression from onset. Treatment options for progressive disease are currently limited.

As the understanding of the disease has evolved, treatment options and treatment approaches have also advanced. The definitions of clinical courses were revised to better reflect underlying MS pathologic condition.9 Importantly, disease activity was added as a temporal qualifier to the MS phenotypes because clinical and radiographic

KEYWORDS

- Multiple sclerosis
- Disease-modifying treatment
- Remyelination therapies
- Neuroprotection therapies
- Treatment approaches

KEY POINTS

- Multiple sclerosis (MS) is a chronic, immune-mediated neurologic disease that affects nearly 1 million people in the United States, is a major cause of disability, and can lead to a reduced quality of life.
- There are currently more than a dozen approved disease-modifying therapies for MS, with varying mechanisms of action, routes of administration, dosing schedule, efficacy, and side-effect profiles.
- Most disease-modifying therapies target active, inflammatory disease that defines relapsing remitting MS, with less treatments available to target neurodegenerative disease.
- The treatment targets, goals, and algorithms are changing as the field learns more about the pathophysiology of the disease.
- New therapies that target remyelination and neurodegeneration are being developed, but more robust data are needed before they are integrated into routine clinical care.

Mellen Center U-10, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
* Corresponding author.
E-mail address: mcginlm@ccf.org

Neurol Clin 39 (2021) 21–33
0733-8619/© 2020 Elsevier Inc. All rights reserved.
neurologic.theclinics.com
disease activity along with disability progression can occur in both relapsing and pro-
gressive disease. This balance of disease activity reflects a combination of inflamma-
tory and neurodegenerative processes that is important to understand in treatment
decision making. This review discusses the evolution of the treatment landscape of
MS, treatment approaches, and future directions.

**DISEASE-MODIFYING THERAPIES**

The first disease-modifying therapy (DMT) was an injectable medication approved by
the Food and Drug Administration (FDA) in 1993. Subsequently, there have been a va-
riety of injectable, oral, and infusion DMTs developed that have unique risks and
benefits.

**Injectables**

Interferon β-1b was the first FDA-approved treatment for RRMS. There are currently 5
formulations of interferon injections available for RRMS. The initial phase 3 IFN-β trials
showed a reduction in relapse rates by 18% to 34% in patients with relapsing MS. Shortly
after the interferons were approved, glatiramer acetate was approved with similar
efficacy. Injectable therapies were the mainstay of MS treatment for more than 15 years, until the first oral medications were approved. The injectable DMTs
have the most long-term safety data, and there are patients who have remained stable
on them for many years with few side effects. However, in the current landscape, use
of injectable therapies has diminished because of the development of alternative
DMTs with improved tolerability and higher efficacy.

**Orals**

Fingolimod, a sphingosine 1-phosphate (S1P) receptor modulator, was the first FDA-
approved oral DMT in 2010, which was a major advancement because of the
improved efficacy and new route of administration. Since this development, there
have been a variety of oral options approved, changing the landscape of treatment
(Table 1). Siponimod and ozanimod are both selective S1P receptor modulators
that were recently approved. These medications, although similar to fingolimod,
have unique side effects and monitoring requirements. All patients started on fingoli-
mod require first-dose observation (FDO) because of the possibility of first-dose
bradycardia from interaction with receptors on cardiac myocytes. Conversely, only
patients with a cardiac history are suggested to undergo an FDO with siponimod,
and there is no FDO recommendation with ozanimod. These varying recommenda-
tions are due to the more selective S1P receptor subtypes of the newer medications.
Teriflunomide, like the S1P receptor modulators, has convenient once-daily dosing,
but with a different mechanism of action (pyrimidine synthesis inhibition). The fuma-
rates are another class of oral medications. The most recently approved fumarate, dir-
oximel fumarate, has the same dosing frequency and mechanism of action as dimethyl
fumarate, but was shown to have improved tolerability, specifically reduction of
gastrointestinal (GI) side effects. Finally, cladribine is unique in the oral medication
group because it has an induction-type dosing schedule of two 5-day cycles
12 months apart. Overall, the oral medications are more efficacious than the inject-
table therapies, except for teriflunomide, which is similar in efficacy to injectables,
and cladribine has the highest efficacy. They are well tolerated, although their side-
effect profile varies. The risk of infections is increased compared with the injectable
therapies, and some may be limited because of other risks, such lymphopenia, in fin-
golimod or dimethyl fumarate and transaminitis with teriflunomide.
<table>
<thead>
<tr>
<th>Year</th>
<th>Approved</th>
<th>Dosing</th>
<th>Medication Class</th>
<th>Phase 3 Trial</th>
<th>Main Outcome</th>
<th>Main Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>2010</td>
<td>Fingolimod</td>
<td>0.5 mg daily</td>
<td>Sphingosine 1-phosphate receptor modulator</td>
<td>FREEDOMS TRANSFORMS</td>
<td>54% decrease in annualized relapse rate</td>
<td>Bradycardia, heart block with first dose, macularedema, elevated liver enzymes, hypertension, headache, varicella-zoster virus (VZV) reactivation</td>
</tr>
<tr>
<td>2019</td>
<td>Siponimod</td>
<td>Initial titration with a final dose of 2 mg daily for CYP2C9 genotypes 1/1, 1/2, 2/2 or 1 mg daily for genotypes 1/3 or 2/3</td>
<td>Selective sphingosine 1-phosphate receptor modulator</td>
<td>EXPAND SPMS, placebo-controlled</td>
<td>21% decrease in risk of 3 mo confirmed disability progression</td>
<td>Bradycardia with first dose, lymphopenia, elevated liver enzymes, macularedema, hypertension, VZV reactivation</td>
</tr>
<tr>
<td>2020</td>
<td>Ozanimod</td>
<td>1 mg daily</td>
<td>Selective sphingosine 1-phosphate receptor modulator</td>
<td>RADIANCE SUNBEAM</td>
<td>38% reduction in ARR, 48% reductions in ARR</td>
<td>Hypertension, nasopharyngitis, edema, varicella-zoster virus (VZV) reactivation</td>
</tr>
<tr>
<td>2020</td>
<td>Ozanimod</td>
<td>1 mg daily</td>
<td>Selective sphingosine 1-phosphate receptor modulator</td>
<td>RADIANCE SUNBEAM</td>
<td>38% reduction in ARR, 48% reductions in ARR</td>
<td>Hypertension, nasopharyngitis, edema, varicella-zoster virus (VZV) reactivation</td>
</tr>
<tr>
<td>2020</td>
<td>Ozanimod</td>
<td>1 mg daily</td>
<td>Selective sphingosine 1-phosphate receptor modulator</td>
<td>RADIANCE SUNBEAM</td>
<td>38% reduction in ARR, 48% reductions in ARR</td>
<td>Hypertension, nasopharyngitis, edema, varicella-zoster virus (VZV) reactivation</td>
</tr>
</tbody>
</table>

(continued on next page)
<table>
<thead>
<tr>
<th>DMT</th>
<th>Year</th>
<th>Approved</th>
<th>Dosing</th>
<th>Medication Class</th>
<th>Phase 3 Trial</th>
<th>Trial Design</th>
<th>Main Outcome</th>
<th>Main Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimethyl fumarate</td>
<td>2013</td>
<td>2013</td>
<td>240 mg bid</td>
<td>Anti-inflammatory/ cytoprotective</td>
<td>DEFINE, CONFIRM</td>
<td>RRMS, placebo-controlled, RRMS, placebo-controlled</td>
<td>53% reduction in ARR, 44% reduction in ARR</td>
<td>Flushing, GI upset, elevated liver enzymes, lymphopenia</td>
</tr>
<tr>
<td>Droximel fumarate</td>
<td>2019</td>
<td>2019</td>
<td>462 mg bid</td>
<td>Converted to same active metabolite as DMF</td>
<td>EVOLVE-MS-2</td>
<td>RRMS, head-to-head comparison to DMF</td>
<td>46% reduction in days with Individual Gastrointestinal Symptom and Impact Scale score of ≥2</td>
<td>Flushing, GI upset, elevated liver enzymes, lymphopenia</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>2012</td>
<td>2012</td>
<td>7 mg or 14 mg daily</td>
<td>Interferes with de novo pyrimidine synthesis</td>
<td>TOWER, TEMSO</td>
<td>RRMS, placebo-controlled, RRMS, placebo-controlled</td>
<td>36% reduction in ARR, 31.5% reduction in ARR</td>
<td>Elevated liver enzymes, hair thinning, headache</td>
</tr>
<tr>
<td>Cladribine</td>
<td>2019</td>
<td>2019</td>
<td>1.75 mg/kg in two 5-d courses 23–27 d apart in year 1 and again 43 wk later</td>
<td>Inhibits DNA synthesis and promote apoptosis in lymphocytes</td>
<td>CLARITY</td>
<td>RRMS, placebo-controlled</td>
<td>57.6% reduction in ARR</td>
<td>Lymphopenia, VZV reactivation, infections</td>
</tr>
</tbody>
</table>
Natalizumab was the first approved infusion DMT for RRMS in 2004. It is a monoclonal antibody against α4-integrin and is a selective adhesion molecule inhibitor, given by a monthly infusion. This therapy dramatically changed the landscape of treatment not only because of its route and frequency of administration but also because of its high efficacy on relapses and MRI activity. Its use has been limited because of the serious risk of developing progressive multifocal leukoencephalopathy (PML). Risk can be stratified by JC virus (JCV) status and index level, but for patients who are seropositive and on the medication for greater than 2 years, the risk climbs to 3 cases per 1000. For this reason, this medication is primarily used in JCV-seronegative patients, and seropositive patients are not typically recommended to continue this medication beyond 2 years. There is evidence that dosing intervals can be extended, which can mitigate PML risks.

Rituximab is a CD20 monoclonal antibody that historically has been used off label for treatment of MS supported by phase 2 placebo-controlled trial evidence demonstrating efficacy in RRMS. This DMT was often used in patients with highly active disease that were JCV seropositive, thus limiting the use of natalizumab. In 2017, ocrelizumab, also a CD20 monoclonal antibody, was FDA-approved for the treatment of RRMS and PPMS based on the results of the OPERA I/II and ORATORIO studies, respectively. Ocrelizumab is different from rituximab because it is humanized, which has the potential to decrease infusion reactions. These medications are becoming more commonly prescribed because of their high efficacy, ease of dosing, and side-effect profile.

Alemtuzumab is a humanized monoclonal antibody that targets the CD52 antigen expressed on T cells, B cells, monocytes, and eosinophils that produces rapid, profound, and prolonged lymphocyte depletion with gradual reconstitution. It is administered for 5 consecutive days during the first cycle followed by a 3-day course 1 year later, with the potential for re-treatment. Even after reconstitution, the cell profile and function are altered, leading to continued efficacy that may not require further treatment. Monitoring is burdensome and includes malignancy screening with annual gynecologic and skin examinations, pretreatment laboratory workup, and monthly blood and urine testing for 4 years after treatment. The monthly monitoring is part of a Risk Evaluation Mitigation Strategy (REMS) program to monitor for autoimmune conditions, such as thyroid disease, glomerular basement membrane disease, and thrombocytopenia. In addition, acyclovir 200 mg to 400 mg twice a day is given prophylactically during the course of treatment and continues until CD4+ lymphocytes recover to at least 200 cells/μL, with a minimum duration of 2 months because of the risk of herpes virus infections and reactivations.

**STEM CELL TRANSPLANT**

Stem cell therapy is of increasing interest in several neurologic conditions, including MS. Particularly, the role of immunoablation and autologous hematopoietic stem cell transplantation (AHSCT) in treatment-resistant relapsing disease is currently under investigation. Despite the variety of DMTs listed above, there is a subset of patients who have continued inflammatory disease activity or are limited by adverse events who may be candidates for AHSCT. Recently, the American Society for Blood and Bone Marrow Transplantation created a task force to review the evidence and provide recommendations regarding treatment-refractory MS as an indication for AHSCT. Their review of retrospective studies found an overall incidence of relapse-free survival at 5 years after transplant of 80% to 87%, with many studies showing Expanded...
Disability Status Scale (EDSS) stability or improvement. They also reviewed several single-arm clinical trials (NCT00278655, NCT01099930, NCT00288626, ACTRN 12613000339752) and 2 randomized controlled trials (NCT00273364, EUDRACT 2007-000064-24) that differed in inclusion criteria, conditioning regimens, primary outcomes, and comparators in the randomized trials. These trials also showed high rates of relapse-free survival, disability stability or improvement, and improved MRI measures. Mortalities across these studies range from 0% to -4.2% and have significantly improved over time. Overall, it appears that AHSCST is most effective and of most benefit in patients with active, relapsing disease despite DMT, and in patients who are younger with a relatively short disease duration, but still ambulatory although accruing disability. There is an ongoing randomized trial evaluating the safety, efficacy, and cost-effectiveness of AHSCT compared with best available therapy (natalizumab, CD20 monoclonal antibodies, and alemtuzumab) in treatment-refractory relapsing patients with the goal of determining the optimal use of this treatment in the current landscape (BEAT-MS, NCT04047628).

TREATMENT STRATEGIES FOR RELAPSING REMITTING MULTIPLE SCLEROSIS

There are currently 9 classes of DMTs that were discussed above. These medications vary in mechanism of action, efficacy, route of administration, and side-effect profiles. With the increasing number of approved therapies, there are a variety of treatment approaches that can be used. Treatment decisions should be tailored to each individual patient with regards to disease phenotype, risk profile, and patient preference, but there are 2 general approaches: escalation and early highly effective treatment.

For an escalation approach, the patient is started on a low- to moderate-efficacy DMT (eg, injectable or oral DMT), and if there is breakthrough disease, the patient’s therapy is escalated to a highly effective choice (eg, monoclonal antibody). This approach has been commonly used because the older medications have a well-established safety profile. Although some patients will remain stable on the first DMT, some will require a change in therapy because of disease activity. Evidence of disease activity is most commonly defined as clinical relapses and/or new lesions on MRI. A stricter target that has been suggested is no evidence of disease activity (NEDA). NEDA-3 includes measures such as clinical relapses, disability progression, and MRI activity, whereas NEDA-4 adds brain volume loss to account for the neurodegenerative process. NEDA has been suggested as a target outcome, but not currently used in clinical practice. With the advent of the newer DMTs, the threshold for escalation has lowered, but is still dependent on comfort of the practitioner and patients using the medications, access to the support needed for the therapies (ie, infusion centers), and cost. The benefit of escalation therapy is minimizing the risk, but the concern is for the potential for undertreatment of disease activity that may lead to accumulation of disability and disease progression.

The alternative approach is to start a highly effective therapy as the first treatment option. Subgroup analysis and observational studies demonstrate starting DMT earlier in the disease course, preferably after the first clinical attack, leads to better long-term clinical outcomes. A goal of the most recent 2017 McDonald criteria revisions was to facilitate earlier diagnosis, allowing for earlier treatment. The DMTs that are considered highly effective include natalizumab, rituximab, ocrelizumab, and alemtuzumab. The tradeoffs to higher efficacy are increased risks, such as infection, autoimmunity, and malignancy, with less long-term safety data for many of these medications. Currently in clinical practice, the decision between treatment strategies is made based on a variety of prognostic indicators and shared decision making.
between the patient and provider. Several demographic and disease characteristics that may suggest a more severe course include male gender, older age at presentation, increased severity and frequency of relapses, higher burden of spinal cord and infratentorial lesions, increased T2 lesions burden, increased contrast-enhancing lesion burden, and increased brain atrophy. Although observational studies suggest that early high-efficacy treatment may have long-term benefits, there is currently no randomized trials that have evaluated the 2 treatment strategies. There are 2 ongoing large, randomized multicenter trials in treatment-naïve RRMS patients who will rigorously evaluate the 2 treatment approaches: Determining the Effectiveness of Early Intensive versus Escalation approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis (DELIVER-MS, NCT03535298) and Traditional versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS, NCT03500328).

PROGRESSIVE DISEASE

There has been a multitude of advances in the treatment of RRMS, but developments in progressive MS treatment have been slow. All the currently available DMTs primarily target inflammatory disease activity, which is typically present to a lesser degree in progressive disease. Progressive patients can have evidence of disease activity, such as superimposed relapses on a progressive decline or MRI activity (eg, new or enhancing lesions). In progressive patients with evidence of disease activity, all the currently available DMTs are now approved for secondary progressive MS with evidence of disease activity. In 2019, the EXPAND phase 3 trial of siponimod demonstrated efficacy in a secondary progressive disease with activity, which led to its approval in both RRMS and Secondary progressive multiple sclerosis (SPMS) with activity. Around this time, the FDA also changed the approval of all DMTs to include both RRMS and active SPMS. This prescribing information change reflected the understanding that progressive disease can have inflammatory disease activity in which current DMTs may be of use. Ocrelizumab is the only approved DMT for PPMS; however, anti-CD20 treatments are likely more effective in younger individuals with evidence of disease activity.

Although the siponimod and ocrelizumab trials demonstrated efficacy in progressive populations, there are still forms of progressive MS that have little inflammatory disease and more neurodegeneration. There have been several negative trials in progressive disease with currently available DMTs. Although these studies did not demonstrate an effect on the primary outcome of disability progression, they helped confirm there is another underlying progress beyond inflammatory activity. There is still a great amount of work needed in the field to discover and develop treatments that target the noninflammatory portion of progressive disease. Remyelination and neuroprotective therapies are 2 potential treatment targets that are now being explored.

Remyelination Therapies

Demyelination of both white and gray matter is a key pathologic feature of MS. Although remyelination does occur, the amount is variable and it decreases with age. Mitochondrial dysfunction and demyelination lead to virtual hypoxia, making axons prone to degeneration and irreversible disability. Oligodendrocytes are the cells that produce myelin and appear crucial for axonal health independent of myelination. It is currently thought that impaired oligodendrocyte precursor cell (OPC) differentiation is involved in remyelination failure, and subsequently that increased OPC differentiation may promote remyelination and have an impact on disability.
recruitment into demyelinated lesions and their differentiation is decreased with age, which parallels decreased remyelination. In addition, the microenvironment around the demyelinated lesion appears to also impair OPC differentiation, adding another challenge to therapy development.

Remyelination is an important target for progressive therapies, as this could theoretically halt disability accrual and potentially reverse some already accumulated disability. One compound that demonstrated potential to promote remyelination was high-dose biotin. Biotin is a cofactor for carboxylases that are expressed in oligodendrocytes in addition to supporting myelin repair by enhancing fatty acid synthesis and protecting against hypoxia-driven axonal degeneration. In 1 phase 3 placebo-controlled trial of high-dose biotin, 12.6% of treated participants compared with no placebo participants met the endpoint of a decreased in EDSS or decrease in timed 25-foot walk; however, the biotin-treated group had more new or enlarging MRI lesions. Unfortunately, the definitive phase 3 trial had no effect on disability improvement.

Another potential remyelination target that has gained interest is opicinumab, which is a humanized monoclonal antibody against the leucine-rich repeat neuronal protein 1 (LINGO-1). LINGO-1 is a cell-surface glycoprotein expressed on CNS neurons and oligodendrocytes and inhibits oligodendrocyte differentiation, myelination, neuronal survival, and axonal regeneration. In vitro and in vivo studies showed that LINGO-1 blockade facilitates axonal remyelination; however, the phase 2 study RENEW that included individuals with a first time episode of optic neuritis failed to show an improvement in the primary outcome of visual-evoked potentials. SYNERGY, another phase 2 trial, failed to show improvement in the primary outcome of disability.

A high-throughput screening approach identified several already available compounds, including antihistamine, that have the potential to stimulate OPC differentiation in vivo. Clemastine is a first-generation antihistamine that has been available over the counter since 1992. It readily crosses the blood-brain barrier and has been shown to promote remyelination through an effect on human OPCs. ReBUILD is a phase 2, randomized, placebo-controlled, cross-over study that showed reduced latency in visual-evoked potentials in MS patients with chronic optic neuropathy. Although this study demonstrated a significant reduction in the primary outcome, it is unclear if the reduction in latency translates to a clinically meaningful improvement in individuals. The overall success of the trial demonstrates the utility of a high-throughput screening approach for identifying potential therapies and introduced a new trial design for evaluating efficacy.

Mesenchymal stem cells (MSCs) are an area of interest in progressive disease for potential remyelination because of their ability to differentiate into various types of cells. These cells can be isolated from bone marrow, adipose tissue, umbilical cord, and other sources. Neural progenitor cells less frequently differentiate into mesodermal cells, which makes them more attractive for transplantation in MS. Although MSCs do not appear to stay in the CNS for long after intrathecal injection (IT), they may have other effects, such as secretion of neurotrophic factors inducing axonal outgrowth and increasing cell survival. One study of neural progenitor MSCs transplanted IT in 3 injections in MS patients showed improved median EDSS, strength, and bladder function. There are currently several studies investigating the use of MSCs in progressive MS given intravenously (IV), IT, and in combination from both autologous and umbilical sources (IV studies: NCT01377870, NCT03778333, NCT02034188, NCT00395200, NCT01745783, NCT01056471, NCT02495766; IT studies: NCT01895439, NCT01938802, NCT03355365, NCT03822858, NCT03799718,
NCT03696485; comparing IV and IT: NCT02166021, NCT03069170). Although there is potential with MSC, there are several concerns, including the risk of infection, infusion-related toxicity, and theoretic risk of malignancy or ectopic tissue formation. In addition, there remain several questions regarding appropriate dosing, route of administration, cell culture protocol, and storage procedures before these therapies should be considered in clinical practice.

Neuroprotective Treatments

The goal of therapies aimed at neuroprotection is to prevent irreversible disability and slow progression. Studies to date have been limited and encompass medications with a variety of mechanisms of action, including simvastatin, phenytoin, ibudilast, α-lipoic acid (ALA), and metformin.

Simvastatin has been proposed as a potential neuroprotective agent because of evidence from animal models demonstrating its impact on multiple immunomodulatory effects. MS-STAT was a phase 2, randomized study of 80 mg simvastatin versus placebo in an SPMS population with a primary outcome of whole brain atrophy. The simvastatin group had a decreased rate of whole brain atrophy compared with placebo.

Ibudilast inhibits cyclic nucleotide phosphodiesterases, toll-like receptor 4, and macrophage inhibitory factor and is able to cross the blood-brain barrier. SPRINT-MS was a phase 2 randomized trial of ibudilast compared with placebo with a primary outcome of rate of brain atrophy in a progressive MS population. Ibudilast had a significantly slower rate of brain atrophy compared with placebo. This study also used 5 advanced imaging metrics as secondary outcomes that may help inform future clinical trials in progressive MS. Further studies of ibudilast would be needed to better understand the impact on clinical measures of disability progression.

There have been smaller studies investigating the potential neuroprotective effects of phenytoin, ALA, and metformin. Phenytoin is a voltage-gated sodium channel inhibitor, which is a mechanism that has been shown to have neuroprotective properties in preclinical trials. One randomized, placebo-controlled phase 2 trial showed that patients with acute optic neuritis who were given phenytoin within 2 weeks of onset had 30% less retinal nerve fiber layer thinning compared with placebo. The clinical relevance of this is not entirely clear, and there are potential serious adverse events with phenytoin administration, such as rash and interactions with other medications, thus limiting its use. ALA has potential neuroprotective effects, as it is a cofactor for the oxidation-reduction portion of mitochondrial reactions and with anti-inflammatory properties. A small phase 2 trial showed benefit in reducing the rate of brain atrophy with a trend toward improvement of the timed 25-foot walk compared with placebo.

Animal studies have suggested that metformin may exhibit neuroprotective effects by protecting against oxidative stress, inducing an anti-inflammatory profile by decreasing T helper 1 (Th1) and Th17 cells, while increasing regulatory T cells, and also may induce remyelination by improving OPC responsiveness.

Finally, the Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial was a phase 2 trial that used a unique multiarm, parallel group randomized trial design to investigate the neuroprotective effects of 3 medications: amiloride, fluoxetine, and riluzole. These 3 compounds were chosen via a systematic review of available evidence of oral neuroprotective drugs that were tested in clinical trials in various neurologic diseases as well as in Experimental autoimmune encephalomyelitis (EAE) models that all have different mechanisms of action targeting axonal pathobiology. None of the medications were superior to placebo for the primary outcome of percentage brain volume change.
All the studies to date evaluating the efficacy of a neuroprotective therapy in MS have demonstrated modest or negative results. The main advances that have emerged are new techniques to identify potential components, such as high-throughput screening, and novel trial designs and outcomes to better evaluate the potential neuroprotective effects.

DISCUSSION

MS treatments have greatly advanced since the first DMT approval in 1993. Most treatments continue to target inflammatory disease activity, but there remains a dearth of options for progressive disease with predominantly neurodegenerative pathologic condition. The multitude of treatment options has changed the landscape of MS management, but ongoing research will help optimize the treatment approaches to maximize the benefit and minimize the risks for individuals with MS. Finally, the field is developing new methods of identifying and assessing a medication’s potential for remyelination and neuroprotection, which will lead to continued advancements.

DISCLOSURE

M.P. McGinley has served on scientific advisory boards for Genzyme and Genentech, receives research support from Novartis, and receives funding from a KL2 (KL2TR002547) grant from Clinical and Translational Science Collaborative of Cleveland, from the National Center for Advancing Translational Sciences (NCATS) component of the NIH.

REFERENCES